Protéines d'inhibition de la différenciation : Questions médicales fréquentes
Nom anglais: Inhibitor of Differentiation Proteins
Descriptor UI:D051796
Tree Number:D12.776.930.329
Termes MeSH sélectionnés :
Colitis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines d'inhibition de la différenciation : Questions médicales les plus fréquentes",
"headline": "Protéines d'inhibition de la différenciation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines d'inhibition de la différenciation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-25",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines d'inhibition de la différenciation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de transcription",
"url": "https://questionsmedicales.fr/mesh/D014157",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription",
"code": {
"@type": "MedicalCode",
"code": "D014157",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine d'inhibition de la différenciation de type 1",
"alternateName": "Inhibitor of Differentiation Protein 1",
"url": "https://questionsmedicales.fr/mesh/D051798",
"about": {
"@type": "MedicalCondition",
"name": "Protéine d'inhibition de la différenciation de type 1",
"code": {
"@type": "MedicalCode",
"code": "D051798",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.329.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine d'inhibition de la différenciation-2",
"alternateName": "Inhibitor of Differentiation Protein 2",
"url": "https://questionsmedicales.fr/mesh/D051797",
"about": {
"@type": "MedicalCondition",
"name": "Protéine d'inhibition de la différenciation-2",
"code": {
"@type": "MedicalCode",
"code": "D051797",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.329.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines d'inhibition de la différenciation",
"alternateName": "Inhibitor of Differentiation Proteins",
"code": {
"@type": "MedicalCode",
"code": "D051796",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Francesco Balestri",
"url": "https://questionsmedicales.fr/author/Francesco%20Balestri",
"affiliation": {
"@type": "Organization",
"name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Roberta Moschini",
"url": "https://questionsmedicales.fr/author/Roberta%20Moschini",
"affiliation": {
"@type": "Organization",
"name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Umberto Mura",
"url": "https://questionsmedicales.fr/author/Umberto%20Mura",
"affiliation": {
"@type": "Organization",
"name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Mario Cappiello",
"url": "https://questionsmedicales.fr/author/Mario%20Cappiello",
"affiliation": {
"@type": "Organization",
"name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Antonella Del Corso",
"url": "https://questionsmedicales.fr/author/Antonella%20Del%20Corso",
"affiliation": {
"@type": "Organization",
"name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Check this out: treatment paradigms in immune-checkpoint inhibitor colitis.",
"datePublished": "2022-11-03",
"url": "https://questionsmedicales.fr/article/36504035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOG.0000000000000892"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cytomegaloviral colitis in primary CMV viraemia in a young immunocompetent adult.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36220260",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2022-249891"
}
},
{
"@type": "ScholarlyArticle",
"name": "Very-Early Onset Chronic Active Colitis with Heterozygous Variants in",
"datePublished": "2022-06-24",
"url": "https://questionsmedicales.fr/article/35748740",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/15513815.2022.2088912"
}
},
{
"@type": "ScholarlyArticle",
"name": "Progress on Regulation of NLRP3 Inflammasome by Chinese Medicine in Treatment of Ulcerative Colitis.",
"datePublished": "2023-04-29",
"url": "https://questionsmedicales.fr/article/37148482",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11655-023-3551-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Engineering fucoxanthin-loaded probiotics' membrane vesicles for the dietary intervention of colitis.",
"datePublished": "2023-04-09",
"url": "https://questionsmedicales.fr/article/37058897",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biomaterials.2023.122107"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de transcription",
"item": "https://questionsmedicales.fr/mesh/D014157"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines d'inhibition de la différenciation",
"item": "https://questionsmedicales.fr/mesh/D051796"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines d'inhibition de la différenciation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines d'inhibition de la différenciation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines d'inhibition de la différenciation",
"description": "Comment diagnostiquer une anomalie des protéines d'inhibition ?\nQuels tests sont utilisés pour évaluer les niveaux de ces protéines ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs tumoraux sont associés à ces protéines ?\nPeut-on utiliser l'imagerie pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines d'inhibition de la différenciation",
"description": "Quels symptômes sont liés à une surproduction de ces protéines ?\nLes symptômes varient-ils selon le type de cancer ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines d'inhibition de la différenciation",
"description": "Peut-on prévenir les anomalies des protéines d'inhibition ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe tabagisme influence-t-il les niveaux de ces protéines ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines d'inhibition de la différenciation",
"description": "Quels traitements ciblent les protéines d'inhibition ?\nLes traitements sont-ils efficaces contre tous les cancers ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils combinés avec d'autres thérapies ?\nComment évaluer l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines d'inhibition de la différenciation",
"description": "Quelles complications peuvent survenir avec des niveaux anormaux ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nY a-t-il des complications spécifiques aux traitements ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines d'inhibition de la différenciation",
"description": "Quels sont les principaux facteurs de risque associés ?\nL'âge influence-t-il le risque d'anomalies ?\nLe sexe joue-t-il un rôle dans le risque ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des maladies associées à un risque accru ?",
"url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Colitis&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des protéines d'inhibition ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les niveaux de ces protéines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et Western blot sont couramment utilisés pour mesurer les niveaux."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent révéler des niveaux anormaux de protéines d'inhibition."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont associés à ces protéines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme le CA-125 peuvent être associés à des niveaux anormaux."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les tumeurs, mais pas directement les protéines."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surproduction de ces protéines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut entraîner des symptômes liés à des tumeurs, comme la douleur."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le type de cancer associé aux protéines."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la fatigue, la perte de poids et des douleurs inexpliquées."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être similaires à ceux d'autres maladies, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver à mesure que la maladie progresse ou se développe."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des protéines d'inhibition ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures de prévention, comme un mode de vie sain, peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent aider à détecter des anomalies précocement."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les niveaux de ces protéines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer les niveaux de protéines et augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les protéines d'inhibition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs spécifiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre tous les cancers ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil moléculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les effets secondaires peuvent inclure des nausées, fatigue et immunosuppression."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils combinés avec d'autres thérapies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par imagerie et tests de suivi des niveaux de protéines."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des niveaux anormaux ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la progression tumorale et la métastase peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent aggraver le pronostic et réduire les chances de survie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications spécifiques aux traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent entraîner des complications comme l'infection."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévenues par un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de cancer et l'exposition à des toxines sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies augmente généralement avec l'âge."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains cancers liés aux protéines peuvent être plus fréquents chez un sexe."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des maladies associées à un risque accru ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent augmenter le risque d'anomalies protéiques."
}
}
]
}
]
}
Immune checkpoint inhibitors (ICI) have become a pillar of cancer therapy for many people around the world. However, up to two-thirds of all patients undergoing ICI therapy will have immune-related ad...
Recent findings include several developments on the leading theories for the mechanisms of ICIC such as the role of the gut microbiome. New emerging therapy strategies include tocilizumab, ustekinumab...
The occurrence of irAEs remains a limiting factor for the use of immunotherapy in cancer treatment. Prompt diagnosis of ICIC with endoscopy and histologic confirmation can lead to early utilization of...
A man in his 20s presented with a 2-week history of fever, fatigue and diarrhoea. On arrival to the emergency department, he had clinical findings of sepsis. The care team initially suspected sepsis s...
A small subset of cases of inflammatory bowel disease (IBD) occurs as a result of single gene defects, and typically occurs in young or very young pediatric patients, referred to as "monogenic very-ea...
A six year-old girl presented to our gastroenterology clinic with LRBA deficiency with a heterozygous mutation at c.1399 A > G, p Met467Val, histopathologic chronic active colitis without granulomas a...
We present a case of monogenic VEO-IBD associated with two heterozygous variants in...
Ulcerative colitis (UC) is a chronic, non-specific intestinal disease that not only affects the quality of life of patients and their families but also increases the risk of colorectal cancer. The nuc...
Extracellular vesicles (EVs) are very attractive as carriers of active components due to their good immunological and their ability to penetrate the physiological barrier that synthetic delivery carri...
Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin αvβ6 (anti-αvβ6) autoantibodies have been described in patients with UC. We tested...
Anti-αvβ6 autoantibodies were measured in 4 longitudinal serum samples collected from 82 subjects who later developed UC and 82 matched controls from a Department of Defense preclinical cohort (PREDIC...
Anti-αvβ6 autoantibodies were significantly higher among individuals who developed UC compared with controls up to 10 years before diagnosis in PREDICTS. The anti-αvβ6 autoantibody seropositivity was ...
Anti-integrin αvβ6 autoantibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes....
Stercoral colitis is inflammation of the bowel wall caused by fecal impaction. Despite reported high morbidity and risk of perforation, little research assessing outcomes is available. This study char...
We performed a retrospective chart review of ED patients with stercoral colitis identified on computed tomography (CT) scan. Of 814, 522 visits to multiple EDs across the US, 269 met the inclusion cri...
Of 269 patients, the median age was 76 years. The most common chief concern was abdominal pain/distension (33.8%). However, abdominal pain was documented as absent in 62.1% of cases. The most common C...
Patients with stercoral colitis often present in a nonspecific manner, and short-term mortality is substantial. In this study, most discharged patients did not receive recommended treatment. This repr...
Whereas Artificial Intelligence (AI) based tools have recently been introduced in the field of gastroenterology, application in inflammatory bowel disease (IBD) is in its infancies. We established AI-...
First, we trained and tested a Convolutional Neural Network (CNN) using 1796 real-world images from 494 patients, presenting with three diseases (IBD [n = 212], ischemic colitis [n = 157], and infecti...
For the image-based CNN, the GBDT algorithm and the hybrid approach global accuracies were .709, .792, and .766, respectively. Positive predictive values were .602, .702, and .657. Global areas under ...
Decision support systems exclusively based on endoscopic image analysis for the differential diagnosis of colitis, representing a complex clinical challenge, seem not yet to be ready for primetime and...
Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by watery diarrhoea and a normal radiological and endoscopic appearance. Concern regarding a potential association betwee...
A systematic review and meta-analysis were performed to evaluate the incidence of MC associated with exposure to drug. The PubMed and Embase databases were searched to identify potential studies for i...
Twelve case-control studies were included in the meta-analysis. The results showed exposure to NSAID (OR, 1.64; 95% CI: 1.14-2.37; p < 0.001), PPI (OR, 2.36; 95% CI: 1.59-3.52; p < 0.001), SSRI (OR, 2...
This meta-analysis indicated that NSAID, PPI, SSRI, or aspirin consumption may increase the risk for MC. Further studies exploring drug-induced microscopic colitis should include control groups with d...
The emerging concept that "the maximized therapeutic efficacy of encapsulates would be achieved by inducing appropriate absorption site and pharmacological signal pathways through smart intervention o...